Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy

by DeAngelo, D J
Published 2012

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

by Ravandi, F, Pigneux, A, DeAngelo, D J, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T, Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W, Smith, B D
Published 2015

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

by Papayannidis, C, DeAngelo, D J, Stock, W, Huang, B, Shaik, M N, Cesari, R, Zheng, X, Reynolds, J M, English, P A, Ozeck, M, Aster, J C, Kuo, F, Huang, D, Lira, P D, McLachlan, K R, Kern, K A, Garcia-Manero, G, Martinelli, G
Published 2015

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia

by DeAngelo, D J, Stevenson, K E, Dahlberg, S E, Silverman, L B, Couban, S, Supko, J G, Amrein, P C, Ballen, K K, Seftel, M D, Turner, A R, Leber, B, Howson-Jan, K, Kelly, K, Cohen, S, Matthews, J H, Savoie, L, Wadleigh, M, Sirulnik, L A, Galinsky, I, Neuberg, D S, Sallan, S E, Stone, R M
Published 2015